Increased catabolism and decreased unsaturation of ganglioside in patients with inflammatory bowel disease

Table 2 Quantitative content GM3 and GD3 gangliosides in intestinal mucosa

	Control (BAP) (n = 6)	Control (CRC) (n = 12)	IBD(n = 11)	Pooled SEM
GM3
μg/g tissue	2.4a,b	1.0a	5.8b	0.8
μg/g protein	62.3c,d	19.2c	77.8d	14.1
mg/mol PL	317.7	379.2	196.9	67.7
GD3
μg/g tissue	1.4	1.6	1.4	0.2
μg/g protein	36.8	31.3	20.2	6.1
mg/mol PL	38.1	17.7	15.4	3.0
GM3/GD3
Tissue	1.7a	1.4a	5.6b	0.90
Protein	1.8a	1.5a	5.6b	0.90
PL	8.4a	19.3 b	20.1b	2.40

Mean total GM3, GD3 and GM3/GD3 content was standardized to wet tissue weight, protein content or phospholipid and reported quantitatively within subject groups. Superscript letters (a, b) denote differences (P < 0.05) among study groups; Superscript letters (c, d) denote differences (P < 0.10) among study groups. SEM: Standard error of the mean; CRC: Colorectal cancer; BAP: Benign adenomatous polyposis; IBD: Inflammatory bowel disease.